<SEC-DOCUMENT>0001558370-25-000354.txt : 20250123
<SEC-HEADER>0001558370-25-000354.hdr.sgml : 20250123
<ACCEPTANCE-DATETIME>20250123151213
ACCESSION NUMBER:		0001558370-25-000354
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250123
FILED AS OF DATE:		20250123
DATE AS OF CHANGE:		20250123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		25549627

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tmb-20250123x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 1/23/2025 07:47:30 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Washington,&#160;D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">FORM&#160;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#160;13a-16 OR&#160;15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOR THE&#160;MONTH OF JANUARY 2025</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">COMMISSION FILE NUMBER 001-38976  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">Genmab A/S</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><br></b><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Exact name of Registrant as specified in its charter)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Carl Jacobsens Vej 30</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2500 Valby</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">+45 70 20 27 28</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;"><br></b><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Address of principal executive offices)</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or&#160;Form&#160;40-F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Form&#160;20-F&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      Form&#160;40-F&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="background:#ffffff;">This report on Form&#160;6-K&#160;shall be deemed to be&#160;</font>incorporated by reference<font style="background:#ffffff;">&#160;in Genmab A/S&#8217;s registration statements on&#160;</font><font style="background:#ffffff;">Form&#160;S-8</font><font style="background:#ffffff;">&#160;(File&#160;No. 333-232693, </font>333-253519, 333-262970 and 333-277273<font style="background:#ffffff;">)&#160;and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SIGNATURE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">nthony</p></div></div></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GENMAB A/S</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BY:</font></p></td><td style="vertical-align:bottom;width:45.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Name: Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Title: Executive Vice President &amp; Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">DATE: JANUARY 23, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXHIBIT&#160;INDEX</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.1127167%;width:102.22%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">O</font></p></div></div></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit</u></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of Exhibit</u></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Company Announcement Dated January 23, 2025: Grant of Restricted Stock Units and Warrants to Employees in Genmab</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20250123xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 1/23/2025 07:47:29 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20250123xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Grant of Restricted Stock Units and Warrants to Employees in Genmab </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Company Announcement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">COPENHAGEN, Denmark; January 23, 2025 &#8211; Genmab A/S (Nasdaq: GMAB) announced today that </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">the Board </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">decided to grant 4,903 restricted stock units and 5,289 warrants to employees of the Company and the Company&#39;s subsidiaries.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,512.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors.</font><font style="font-family:'Arial','Helvetica','sans-serif';background:#ffffff;"> Information con</font><a name="OpenAt"></a><font style="font-family:'Arial','Helvetica','sans-serif';background:#ffffff;">cerning Genmab&#8217;s restricted stock unit program can be found on www.genmab.com under </font><font style="font-family:'Arial','Helvetica','sans-serif';background:#ffffff;">Investors &gt; Governance &gt; Compensation &gt; Restricted Stock Units.</font><font style="font-family:'Arial','Helvetica','sans-serif';background:#ffffff;">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The exercise price for each warrant is DKK 1,512. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 466.97.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the Board of Directors on February 23, 2021. Information concerning Genmab&#8217;s warrant schemes can be found on www.genmab.com under </font><font style="font-family:'Arial','Helvetica','sans-serif';">Investors &gt; Governance &gt; Compensation &gt; Warrants.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a name="_Hlk34744061"></a><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Genmab</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab&#8217;s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';">) antibody medicines.&#8239;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com&#8239;and follow us on LinkedIn and X.</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br><br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Contact:</b></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Marisol Peron, Senior Vice President, Global Communications &amp; Corporate Affairs</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +1 609 524 0065; E: mmp@genmab.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Andrew Carlsen, Vice President, Head of Investor Relations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +45 3377 9558; E: acn@genmab.com </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 02</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 1/2</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20250123xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Grant of Restricted Stock Units and Warrants to Employees in Genmab</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;"><a name="_Hlk34743654"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">This Company Announcement contains forward looking statements. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend&#8221; and &#8220;plan&#8221; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#8217;s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab&#8217;s </i><font style="font-size:10pt;"><a name="_Hlk35592020"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">most recent Annual Report on Form 20-F </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; Genmab in combination with the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HuMax</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoHexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">, HexElect</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174; </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">and KYSO</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 02</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 2/2</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20250123xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250123xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ ,H# 2(  A$! Q$!_\0
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M;')RHZ9S\[_L\ZYXCL?C+X7CT*[NS<7=]''<PK(S)- 3F7S!T(";CD]" >M
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4I5JU,PQ5N:I9)+5**\W:[?4__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
